Please note that any funds granted from the FSHD Canada Foundation cannot be used to cover more than ten percent (10%) of overhead costs.
Matrix Bound Vesicles for the Treatment of DUX4-mediated Muscle Pathology
Investigators: Collaborative study between Dr. Michael Kyba (UMN) and Dr. Stephen Badylak (UPMC) This study will investigate the effects of treating muscle with GMP produced matrix-bound vesicles (MBVs) in the iDUX4pA/HSA…
Read MorePhenotypic characterization of FSHD-like FLExDUX4 minipigs
Investigator: Peter L. Jones, PhD, University of Nevada, Reno School of Medicine All forms of FSHD are caused by misexpression of DUX4 (double homeobox protein 4) in skeletal muscles; thus, the…
Read MoreMatrix Bound Nanovesicles (MBV) as a Therapy for FSHD
Investigator: Dr. George Hussey, University of Pittsburgh Regenerative Medicine provides an alternative FSHD treatment strategy for promoting new tissue growth using Extracellular Matrix (ECM) bioscaffolds. ECM bioscaffolds serve as a biochemical…
Read MoreWorking Towards an ASO Treatment for FSHD2 Patients
Investigator: Dr. Stanley Crooke FSHD is a rare disease. FSHD2 is even more rare. Only 5% of all FSHD patients have FSHD2. We don’t want them to get left behind. The…
Read MoreAccelerating Canadian Regulatory Approvals
The Objective Several promising treatments for FSHD are going into clinical trials very soon. Hopefully, these therapies will be approved for use by FSHD patients in the next couple of…
Read MoreDiagnostics
Investigator Takako Jones, PhD (University of Nevada, Reno School of Medicine) Current FSHD diagnostics are complex, expensive, and not widely available. In addition, the disease itself has wide variability in…
Read More